Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 12Dermatologic 1

Conditions

Melanoma 864Lymphoma, T-Cell, Cutaneous 143Uveal Melanoma 96Skin Neoplasms 96Mycosis Fungoides 95Sezary Syndrome 81Carcinoma, Basal Cell 76Neoplasm Metastasis 68Lymphoma 64Lymphoma, Non-Hodgkin 63Keratosis, Actinic 61Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 57Carcinoma, Renal Cell 55Carcinoma, Non-Small-Cell Lung 54Lymphoma, B-Cell, Marginal Zone 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 52Lymphoma, Follicular 52Hodgkin Disease 52Lymphoma, Large-Cell, Immunoblastic 50Carcinoma, Merkel Cell 50Burkitt Lymphoma 49Brain Neoplasms 46Multiple Myeloma 44Lymphoma, Large-Cell, Anaplastic 41Recurrence 40Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40Breast Neoplasms 40

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibromatoses × Dermatologic × Clear all
NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Sutter Health

Phase 2 Recruiting
10 enrolled
CNSDermatologic

Melanoma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡